374. Intranasal esketamine in treatment-resistant bipolar depression maintained on long-acting aripiprazole
The International Journal of Neuropsychopharmacology September 1, 2026 S Makhoul, N Abdulameer
Abstract Background Esketamine intranasal spray is FDA-approved for treatment-resistant depression (TRD), but it is not licensed for use in bipolar disorder due to the risk of antidepressants inducing manic or hypomanic episodes. To date, there is limited data on the use of intranasal esketamine in bipolar disorder, and no previous reports of using esketamine as an add-on treatment in patients...